Uncle Sam Vs. Pfizer: The $160 Billion Battle Over Taxes, Consolidation

Monday, November 23, 2015

YOUR BEST SOURCE FOR THE UNBIASED MARKET COMMENTARY YOU WON’T GET FROM WALL STREET

You can also access this issue on our website.

Uncle Sam Vs. Pfizer: The $160 Billion Battle Over Taxes, Consolidation

By Mike Larson

Market Roundup Dow 17,792.68 (-31.13) Gold $1,067.90 (-$8.40) Oil $41.86 (-$0.04) Drugmaker Pfizer (PFE) just threw a gauntlet down at Uncle Sam’s feet. The U.S. pharmaceutical giant said it would acquire Allergan PLC (AGN) in a transaction worth about $160 billion in stock, cash, and debt. The deal would combine drugs and vaccines that treat everything from cancer to arthritis to pneumonia, and the wrinkle-fighting treatment Botox and erectile dysfunction product Viagra, under one roof — creating the world’s largest Big Pharma firm. To read the rest of Mike Larson’s Afternoon Edition, click here ...

Mike Larson graduated from Boston University with a B.S. degree in Journalism and a B.A. degree in English in 1998, and went to work for Bankrate.com. There, he learned the mortgage and interest rates markets inside and out. Mike then joined Weiss Research in 2001. He is the editor of Safe Money Report. He is often quoted by the Washington Post, Reuters, Dow Jones Newswires, Orlando Sentinel, Palm Beach Post and Sun-Sentinel, and he has appeared on CNN, Bloomberg Television and CNBC.

The investment strategy and opinions expressed in this article are those of the author’s and do not necessarily reflect those of any other editor at Weiss Research or the company as a whole.